Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals has reported Q1 2024 net sales of $75.9 million for their drug DAYBUE™, with full-year sales projected between $370-420 million. Approximately 25% of Rett syndrome patients in the U.S. have started treatment with DAYBUE™, showing strong persistence rates. The company is also making strides in international markets, with regulatory filings and reviews underway in Canada, Europe, and Japan.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
